![Osivax Osivax](https://beta.motherbase.ai/media/logo/136634_agt0TDd.jpeg)
Osivax
Pioneering A New Class of Universal Vaccines
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.
HOME - Osivax
Osivax is developing a new class of universal vaccines empowering both arms of the immune system.